The molecular diagnosis of TSC is established by identifying a pathogenic variant of TSC1 or TSC2, irrespective of the clinical finding (Krueger and Northrup, 2013; Northrup et al., 2021). This evidence concerns the gene TSC2 and tuberous sclerosis.